Status:
TERMINATED
Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer
Lead Sponsor:
University of California, San Francisco
Conditions:
Thyroid Gland Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This pilot clinical trial studies how well Gallium-68 prostate specific membrane antigen positron emission tomography (PET) work in diagnosing patients with thyroid cancer. Diagnostic procedures, such...
Detailed Description
PRIMARY OBJECTIVES: I. To determine the feasibility and utility of Gallium Ga 68-labeled PSMA-11 (68Ga-PSMA) PET imaging in patients with thyroid cancer. SECONDARY OBJECTIVES: I. To assess the corr...
Eligibility Criteria
Inclusion
- History of thyroid cancer
- Whole body 18F-FDG PET/computed tomography (CT) or I-131 scintigraphy within the past 90 days of the scheduled 68Ga-PSMA PET demonstrating uptake
- Creatinine =\< 3.0 mg/dL
- Ability to understand a written informed consent document, and the willingness to sign it
Exclusion
- Patients who have had active infection within 15 days of study enrollment that may be considered to interfere with 68Ga-PSMA PET imaging by the study investigators
- Patients who are unable to have placement of intravenous line access
- Pregnant or breastfeeding women
- Patients not capable of undergoing a PET/MRI study due to weight, claustrophobia, or inability to lie still for the duration of the exam
Key Trial Info
Start Date :
March 19 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2020
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT03463889
Start Date
March 19 2018
End Date
October 31 2020
Last Update
June 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94115